Viewing data from:

ZYPREXA RELPREVV

NDA

OLANZAPINE PAMOATE | N022173 | CHEPLAPHARM REGISTRATION GMBH

3 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

1 trial from ClinicalTrials.gov, 1 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia NCT06253546	Phase 1	Completed	Teva Branded Pharmaceutical Products R&D LLC	24	2024-03-28 → 2025-06-12

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Medicare Part D Spending

CMS annual spending data for Zyprexa Relprevv (2023)

Total Spending

$4.1M

Total Claims

3,721

Beneficiaries

335

Avg Cost/Unit

$1011.85

Spending Trend

$6.0M(2019)→$5.4M(2020)→$5.2M(2021)→$4.8M(2022)→$4.1M(2023)

YoY Change:+0.9%

5yr CAGR:+0.2%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

29 letters from Drugs@FDA

Date	Submission	Document
May 11, 2026	SUPPL -40	View Letter (PDF)
May 11, 2026	SUPPL -43	View Letter (PDF)
Feb 3, 2026	SUPPL -50	View Letter (PDF)
Feb 7, 2025	SUPPL -47	View Letter (PDF)
Apr 30, 2021	SUPPL -39	View Letter (PDF)
Jan 14, 2021	SUPPL -37	View Letter (PDF)
Apr 24, 2020	SUPPL -34	View Letter (PDF)
Apr 23, 2020	SUPPL -35	View Letter (PDF)
Apr 22, 2020	SUPPL -36	View Letter (PDF)
Oct 23, 2019	SUPPL -30	View Letter (PDF)
Apr 24, 2019	SUPPL -32	View Letter (PDF)
Mar 29, 2018	SUPPL -29	View Letter (PDF)
Dec 1, 2017	SUPPL -27	View Letter (PDF)
Mar 2, 2017	SUPPL -28	View Letter (PDF)
Mar 2, 2017	SUPPL -26	View Letter (PDF)
Oct 14, 2016	SUPPL -25	View Letter (PDF)
Sep 18, 2015	SUPPL -24	View Letter (PDF)
Dec 23, 2014	SUPPL -15	View Letter (PDF)
Nov 3, 2014	SUPPL -23	View Letter (PDF)
Mar 29, 2013	SUPPL -18	View Letter (PDF)
Aug 7, 2012	SUPPL -14	View Letter (PDF)
Aug 7, 2012	SUPPL -8	View Letter (PDF)
Aug 7, 2012	SUPPL -10	View Letter (PDF)
Dec 6, 2010	SUPPL -9	View Letter (PDF)
Jul 12, 2010	SUPPL -4	View Letter (PDF)
Jun 2, 2010	SUPPL -3	View Letter (PDF)
Jun 2, 2010	SUPPL -6	View Letter (PDF)
May 3, 2010	SUPPL -2	View Letter (PDF)
Dec 29, 2009	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — EQ 210MG BASE/VIAL

RLD

0 patents0 exclusivities▴

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Approved: Dec 11, 2009

No patent or exclusivity listings for this strength.

#002 — EQ 300MG BASE/VIAL

RLD

0 patents0 exclusivities▾

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Approved: Dec 11, 2009

#003 — EQ 405MG BASE/VIAL

RLD

0 patents0 exclusivities▾

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Approved: Dec 11, 2009